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Abstract  
The unstructured abstract of 200 words maximum should summarize the main points of the 
article. All information mentioned in the abstract must be addressed somewhere in the main 
article. The abstract should not contain references or display item citations. 
 
1. Introduction [suggested 500 words, is 544 words – 8 refs] Mary Robertson 
 
Thoughts for Mary 
- Your word count when combining  sections 1 and 2  is 1001 (1000 limit)- so OK 
- please check refs are as you intended, especially those flagged below 
- note that the author guidelines ask that we “annotate 2–3 references from each main 
section describing why these papers are of particular importance” – I guess this 
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- Timeline can be one display item but any others? (DSM criteria in a box maybe a bit 
boring, but would fit) Agree - boring but would fit 
NRDP – Gilles de la Tourette Syndrome    2 
 
 
 
Gilles de la Tourette Syndrome (GTS), a reasonably common disorder, has had a long, 
tortuous and somewhat controversial history. First and well described in the 18th century1,2, 
the main features of GTS have, however, remained fairly constant. The core diagnostic 
features are multiple motor and one or more vocal (phonic) tics lasting for over a year. In 
addition, almost pathognomic, but not necessary, features described in the early 
documentations include coprolalia (involuntary, inappropriate swearing), and echo-
phenomena (copying behaviours), as well as many co-morbidities and psychopathologies3.  
 
GTS was originally described in France and the majority of early literature came from 
Europe.   The World Health Organisation (ICD, now ICD 10; F95.2) criteria have remained 
reasonably constant over time and refer to GTS as a syndrome.  The American DSM 
diagnostic criteria have been in place since 1952, when "tics" were first mentioned, but GTS 
was first included in DSM-III in 1980, giving "birth" to a tranche of publications, in 
particular from the USA: In the DSM system, currently in its 5th edition4, GTS is referred to 
as a disorder (307.23). Aspects of the DSM criteria have changed over the years, including 
age at onset, presence of impairment and "marked distress" and suppressibility. Other 
diagnostic systems exist, such as the Chinese Diagnostic Criteria (stipulating distress), but a 
majority of clinicians and in particular researchers opt for the DSM criteria as comparison of 
data is important5. The establishment of diagnostic criteria that resulted in research world-
wide has led the scientific community to view GTS as a common disorder.  
 
As with many syndromes, there have been numerous well-designed clinical and 
longitudinal studies that have clarified the clinical features, co-morbidities, and co-existent 
psychopathologies and resultant impairments associated with GTS, highlighted by the 
volume of Quality of Life (QoL) studies now being published.  Many epidemiological studies 
have also been undertaken, but with inconsistent results. Further, many GTS-specific scales 
and standardised schedules such as diagnostic confidence, measurement of severity, QoL, and 
assessment of both co-morbidities and co-existent psychopathologies are currently available. 
Large international collaborative consortia are engaged in studies exploring aetiological 
factors in particular, and some international treatment studies are also underway. Perhaps as a 
result of earlier small patient numbers, the treatment trials have given good clues to 
management, but unsurprisingly systematic reviews and meta-analyses have been hampered, 
giving disappointing,  if not unexpected, results. Intriguingly medications from the typical 
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antipsychotic family including haloperidol, which first had documented success in 19616,7 are 
still being used, although successive generations of "atypicals" are currently more in vogue, 
as are medications such as alpha-2-adrenergic  agonists. Interestingly, haloperidol remains 
the only medication prescribed on licence in many parts of the world.  In contrast to disorders 
such as ADHD, in which it is clear which treatments work and which do not require further 
study8, a variety of treatment studies in GTS are still being undertaken, including using other 
medications (trying to improve efficacy and reduce side effects), behavioural therapies, deep 
brain stimulation (for refractory cases), and other more "alternative" methods such as 
"orthotics" (teeth braces). The GTS community has to first agree on how common GTS is and 
then seek funding for research in the areas of major importance. 
 
2. Epidemiology [suggested 500 words, is 444 words, 6 additional refs] Mary Robertson 
GTS was for many years thought to be not only very rare, but a bizarre curiosity, with 
sporadic case reports peppering the literature. The belief that GTS was uncommon at the very 
least was held by many until Comings9 controversially suggested that GTS occurred in 
between 0.66% and 1% of the general population, mostly in boys. Some controversy has 
reigned ever since, with a wide prevalence range being reported ( 0.25% - 5.7% )3. Studies 
have varied enormously in methodology, including reported "cases" actually being 
hospitalised for their GTS10 (i.e., not a true prevalence study); and the "cases" not being 
interviewed/assessed directly (4/21 [19%] of available studies).  In addition, other 
investigations were conducted by telephone, have included a variety of age ranges (4-17 
years), varying assessment methods (1-3 stages) and different cohorts (birth cohort versus 
school pupils). Finally, different assessment schedules were used in different studies.  
 
The investigations conducted in mainstream schools in Colombia, Denmark, Iran, Israel, 
Italy, Poland, Spain, Sweden, the USA and UK showed a somewhat higher prevalence 
compared with those from the Far East. The differing results from the Far East studies may 
be because the Chinese Diagnostic System requires both impairment and distress3, which 
were included but subsequently excluded from DSM.  
 
It has been suggested that GTS does not occur in Sub-Saharan Black African populations 
potentially due to genetic factors11. The comparison with myotonic dystrophy, which does not 
occur in Sub-Saharan Black African people, has been made: Non-African populations have a 
subset of the haplotype diversity present in Africa, as well as a shared pattern of the allelic 
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association (CTG)18-35 alleles (normal range) which were observed in only North-Eastern 
African and non-African populations12. 
 
Relatively recent reviews by experts have suggested world-wide GTS prevalence rates to 
be as low as 0.5% - 0.7 %13 and as high as 0.85% - 1%3,11.  A recent meta-analysis of 
childhood studies reported a prevalence rate of 0.77% - but when only boys were accounted 
for, the prevalence rose to 1.06%14.  World-wide figures in general are somewhat higher than 
many studies from the USA: This may partially reflect the USA having relied on the idea that 
GTS is a "rare disorder", which may have biased results (e.g., CDC studies). The lower rates 
in an Israeli study could be because of the older ages (16-17 years) and because participants 
were military recruits, who it was suggested might have hidden their symptoms. Two studies 
from Denmark, based on national GTS registers, suggest that the incidence of GTS may be 
rising. It is suggested, however, that this may reflect an increase in awareness of GTS. 
Finally, GTS is more common in people with both autism spectrum disorder (ASD) and 
learning disabilities3.  
 
3. Mechanisms/pathophysiology  
3a.  Neurotransmitter abnormalities (suggested 500 words, is 1106 words excluding 
figure (caption another 230 words), 21 additional refs) Harvey Singer 
 
Thoughts for Harvey 
- Will need to reduce text overall 
- We need copyright permission for the Figure? Or ”tweak”?  
- note that the author guidelines ask that we “annotate 2–3 references from each main 
section describing why these papers are of particular importance”.  In this section 
please ask Harvey Singer to do 1 (30 to 50 words is ideal -70 words maximum). 
- There was a reference in your list that I don’t think was cited.  Important to include? 
(Tian Y, Gunther JR, Liao IH, Liu D, Ander BP, Stamova BS, Lit L, Jickling GC, Xu H, Zhan X, Sharp FR. GABA- and 
acetylcholine-related gene expression in blood correlate with tic severity and microarray evidence for alternative splicing in 
Tourette syndrome: a pilot study. Brain Res. 2011; 1381:228-236.  
- Some minor comments in text to review 
 
 In GTS, there is broad consensus that the functional alteration resides within cortical-
striato-thalamo-cortical (CSTC) circuits.  Which one, or combination, of the multiple 
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neurotransmitters located within these pathways is the primary pathological factor remains to 
be determined.  In general, neurochemical hypotheses are derived from data acquired from 
several areas including medication trials; quantification in CSF, blood, and urine; 
neurochemical assays on post-mortem brain tissues; PET/SPECT/MR spectroscopy studies; 
and genetic analyses. In this section, we will briefly review those neurotransmitters with 
important roles in conveying messages via CSTC circuits and are likely candidate 
abnormalities in GTS. 
 
Dopamine 
Evidence supporting a dopaminergic abnormality in GTS is derived from therapeutic 
responses to dopamine antagonists, data from post-mortem studies, and a variety of nuclear 
imaging protocols15.  Hypotheses regarding dopamine abnormalities have included 
presynaptic, intrasynaptic, and postsynaptic dysfunctions.  Suggested presynaptic alterations 
include a developmental hypofunction of dopamine neurons, hyperinnervation, and an 
increased number of dopamine transporters.  Postsynaptic studies have reported variably 
increases in the number of striatal and cortical dopamine receptors.  Other investigations, 
based on an increased release of dopamine following amphetamine stimulation, have 
suggested a potentially unifying hypothesis involving the tonic release of dopamine16.  
Further supporting an involvement of dopaminergic systems is the significant interaction with 
both glutamatergic and GABAergic neurotransmitter systems17.  Mouse models evaluating a 
dopamine abnormality have included DAT knockdown and D1CT-7 mice. Candidate gene 
association studies have reported variations in dopamine receptors, transporters and 
catabolising genes, however, sample sizes have been small and results variable18. 
 
Glutamate 
Suggestive evidence that the glutamatergic system has a role in GTS includes its 
essential role in pathways involved with CSTC circuits; and extensive interaction between the 
glutamate and dopamine neurotransmitter systems; and a beneficial therapeutic effect of 
glutamate-altering medications on obsessive-compulsive symptoms15,17.  Reduced levels of 
glutamate were identified in post-mortem globus pallidus interna (GPi), globus pallidus 
externa (GPe), and substantia nigra pars reticulata (SNpr) regions19.  In contrast, glutamate 
was increased within the striatum and premotor cortex when measured by 7T MR 
spectroscopy20.  Animal models support a role for cortico-striatal glutamatergic afferents in 
the generation of tic-like movements21.  Therapeutically, tic suppression did not differ from a 
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placebo control group following treatment with either a glutamate agonist (D-serine) or a 
glutamate antagonist (riluzole)22.  A missense mutation in the glutamate transporter gene 
(SLC1A3) has been identified in a small number of GTS patients15,23. 
 
Gamma-Aminobutyric Acid (GABA) 
An alteration of GABA is supported by post-mortem, PET and MR spectroscopy 
studies15.  In the striatum, post-mortem studies have identified a reduction of GABAergic 
parvalbumin containing interneurons, however, 7T-MRS showed elevated concentrations of 
GABA within the striatum20.  PET imaging of GABAA using [(11C)] flumazenil showed 
decreased binding bilaterally in the ventral striatum, globus pallidus, thalamus, amygdala and 
right insula24.  In the cortex, a deficiency of inhibitory interneurons is suggested by a 
reduction of short-interval intracortical inhibition measured by transcranial magnetic 
stimulation and a reduction of GABA measured by 3T MRS in the primary sensorimotor 
cortex25.  In contrast, 7T-MRS has shown elevated concentrations of GABA within the 
supplementary motor area26.  In rodent and primate models, disruption of striatal and cortical 
GABAergic connectivity by local injections of GABAA antagonists has produced tic-like 
behaviors21,26,27.  Other supporting evidence for GABA involvement includes the beneficial 
therapeutic effect of benzodiazepines and an association between GABA-related genes and 
tic severity28. 
 
Acetylcholine 
Results of pharmacological studies using agents that affect nicotinic and muscarinic 
receptors (e.g., transdermal nicotine, mecamylamine, donepezil) have been variable. Post-
mortem studies have shown a decrease in choline acetyltransferase containing striatal 
interneurons, supporting reports of an anatomical reduction of cholinergic interneurons15.  In 
mice, ablation of 50% of cholinergic interneurons in the dorsomedial striatum caused no 
effect, whereas ablation in the dorsolateral striatum plus a stressful stimuli or amphetamine 
challenge caused tic-like stereotypic behaviours29.  Striatal cholinergic interneurons may co-
opt dopamine terminals and drive GABA release30. 
 
Serotonin 
Evidence supporting serotonergic involvement in GTS includes reduced serum and CSF 
levels of serotonin and tryptophan, and PET imaging showing diminished serotonin 
transporter binding capacity15.  Reported findings, however, may be associated with the 
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presence of OCD.  PET imaging of tryptophan (alpha-[11C] methyl-L-tryptophan) uptake 
demonstrated decreased uptake in the dorsolateral prefrontal cortical regions and increased 
uptake in the caudate and thalamus31.  Polymorphic variants of tryptophan hydroxylase 2 and 
the serotonin transporter gene (SLC6A4) have been reported, but there are no differences in 
the serotonin receptor HTR2B gene15,32. 
 
Norepinephrine 
Evidence for a NE mechanism in GTS is limited and partly based on the therapeutic 
effect of alpha-adrenergic agonists (clonidine and guanfacine)15.  Clonidine, however, also 
decreases the release of glutamate and regulates spontaneous and glutamate-modulated firing 
activity in medial frontal cortical pyramidal neurons. Measurements of NE are normal in 
post-mortem cerebral cortex, basal ganglia and plasma; and levels of its metabolite, 3-
methoxy-4-hydroxyphenylethylene glycol are normal in plasma and CSF, but variable in 
urine.  Alpha-receptor densities have been variable in post-mortem cortex, and either normal 
or increased in BA10 and BA11. The later, if confirmed, could lead to a reduction in the basal 
release of dopamine, since activation of α-2A receptors has been shown to inhibit dopamine 
release in the prefrontal cortex.  
 
Histamine 
Histamine is a monoamine neurotransmitter synthesized from histidine via L-histidine 
decarboxylase (HDC).  A heterozygous nonsense point mutation in exon 9 of the HDC gene 
has been identified in a single family with tics33.  To date, however, this mutation has not 
been identified in other families15.  Results in several animal models, including a HDC 
knockout mouse, support a role for deficient HDC in GTS34,35.  A clinical trial with the H3 
receptor antagonist (AZD5213) is currently in progress (Clinical Trials.gov ID: 
NCT01904773).   
 
Endogenous opioids 
The endogenous basal ganglia opioid system interacts with dopamine and other 
neurotransmitters.  Dynorphin A [1-17] immunoreactivity was decreased in a severely 
affected patient with GTS within striatal fibres projecting to the GPe.  Dynorphin A [1-8], 
was increased in the CSF of people with GTS; the concentration of this opiate correlated with 
the severity of obsessive compulsive symptoms, but not with tic severity.  The use of the 
opiate antagonist naloxone in the treatment of tics has produced conflicting results, whereas 
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several studies have suggested that cannabinoids (smoking marijuana or using oral delta-9-
tetrahydrocannabinol) has a beneficial effect on tics.  Limited SPECT studies analysing the 
cannabinoid CB1 receptor with [123I] AM281 have been published.  GTS is not associated 
with mutations in the central cannabinoid receptor (CNR1) gene.  
 
Summary 
Neurochemically, in GTS the strongest evidence continues to favour a major role for 
dopamine.  However, as emphasised in this section, there is expanding evidence to support an 
important role for other neurotransmitters.  See Figure XXXXX.  Recognising the complexity 
of interactions between potential neurotransmitters, it remains likely that several interacting 
neurotransmitter systems are involved. Clearly, our current understanding of this disorder is 
incomplete and further study is required.     
 
 
Figure XXXXXX.  Neurotransmitters in CSTC circuits 
 
Figure caption 
Dopamine:  Substantia nigra pars compacta (SNpc) outputs synapse on i) presynaptic 
receptors located on glutamatergic fibre terminals (inhibitory); ii) striatal projection neurons 
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(SPN, also known as, medium sized spiny neurons) containing D1 receptors (direct pathway); 
enhancing glutamatergic cortical/thalamic stimulation; iii) SPN containing D2 receptors 
(indirect pathway); reducing glutamatergic cortical/thalamic stimulation; and iv) striatal 
interneurons.   The ventral tegmental area (VTA) provides dopaminergic innervation to the 
cortex, primarily to the frontal lobe and ventral striatum. 
 
Glutamate: The excitatory neurotransmitter of cortico-striatal projection neurons, as well as 
output neurons from the subthalamic nucleus (STN) and thalamo-striatal and thalamo-cortical 
projections.  Frontal glutamatergic afferents modulate VTA and SNpc dopaminergic neurons.   
 
GABA: GABAergic inhibitory SPNs form two efferent pathways from the striatum - the 
“direct” (striato-globus pallidus interna (GPi) and “indirect” (striato-globus pallidus externa 
(GPe) pathways.  The direct pathway is ultimately movement activating, whereas the indirect 
pathway is more inhibitory.  Cortical and several striatal interneurons utilise GABA.    
 
Acetylcholine:  Cholinergic large aspiny striatal interneurons influence both SPNs and local 
interneurons.  
 
Noradrenaline:  Noradrenergic (NA) fibres from the locus coeruleus project to the cerebral 
cortex. 
 
Serotonin: Medial raphe (MR) serotoninergic projections innervate the striatum, SNpc, VTA, 
nucleus accumbens and prefrontal cortex.   
 
Histamine: G-protein coupled histamine 3 receptors (H3) are located post-synaptically on 
SPNs and modulate dopamine neurotransmission.   
 
Opiate systems:  GPe is rich in enkephalin; GPi is rich in dynorphin, and the ventral striatum 
contains a mixed distribution.  
 
3b.  Immune and environmental influences in GTS (suggested 500 words, is 536 words, 
13 additional refs) Davide Martino 
 
Thoughts for Davide 
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Increasing evidence links the crosstalk between neural and immune/inflammatory 
mechanisms to the pathogenesis of GTS, with relevant analogies to other neurodevelopmental 
disorders like ASD and schizophrenia. Recapitulating a model elaborated for psychosis36, 
pre- and peri-natal factors (e.g., infections, maternal stress during pregnancy, gestational 
smoking)37 could, on a background of genetic vulnerability, trigger the ‘priming’ of glial cells 
belonging to the monocytic/macrophagic lineage, e.g., microglia, which are highly involved 
in synaptic formation and elimination. Later ‘hits’ (psychosocial stressors, infections) could, 
at a central level, activate the microglia, thus influencing synaptic plasticity close to symptom 
onset, and enhance peripheral immune/inflammatory responses38,39.  Initial evidence suggests 
that these later ‘hits’ might contribute to the ‘waxing and waning’ course of tics in an 
interactive manner. For example, the predictive effect of psychosocial stressors upon tic and 
obsessive compulsive severity becomes three times stronger when an infection (e.g., a group 
A streptococcal pharyngitis) co-occurs with raised psychosocial stress levels40.  Exploring the 
effect of ‘early’ and ‘late’ environmental influences in the context of face-valid animal 
models of tic generation, such as the ‘striatal disinhibition’ model41, would add to our 
understanding of their complex aetiology. 
 
The genetic basis of the dysregulation of immune-mediated mechanisms in GTS is 
poorly understood. In particular, the relative contribution of meiotic genetic variants, somatic 
mutations and epigenetic influences remains unknown. A study on a Danish healthcare 
population registry has shown that a maternal history of autoimmune disorders is associated 
with a 29% higher risk of GTS in the male offspring42.  However, this finding does not clarify 
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whether this association depends on inherited genetic factors, whether it involves 
transplacental transfer, or is merely epiphenomenal. Likewise, the interesting association 
between tics in the context of ADHD and common allergies is still unexplained43. 
 
Direct evidence of altered function of CNS immune cells in GTS is limited, but 
intriguing. The post-mortem analysis of the striatal transcriptome of 9 patients with GTS and 
9 closely matched control individuals showed a widespread up-regulation of inflammatory 
response transcripts related to the activity of cells of the macrophage/monocyte lineage, e.g., 
microglia44.  Some of these transcripts reflect the expression of ‘hub’ genes that are crucial in 
the regulation of both innate and adaptive immune mechanisms. In addition, there is 
preliminary in vivo evidence of activated microglia in the caudate of children with GTS, 
obtained using a common PET ligand for this cell type (PK11195)45.  These early findings 
support the hypothesis that immune-competent neural cells play an important role in the 
pathophysiology of GTS across different age periods, which is sustained by functional 
interactions with cortico-basal ganglia circuits ranging from early influences on 
synaptogenesis and circuit formation to post-developmental influences on circuit activity.  
The analysis of peripheral lymphoid and myeloid immune cells also indicates an up-regulated 
expression of transcripts which control pathogen recognition and cell-mediated innate and 
adaptive response, from early childhood to adolescence46.  Interestingly, some of these 
transcripts involve cholinergic and noradrenergic signalling (relevant to pathogen 
recognition) as well as GABAergic machinery (relevant for its immunesuppressant properties 
both at a central and a peripheral level)47,48.  In addition, clinical studies reported several 
immunological changes in the periphery (e.g., dysgammaglobulinemia, decreased number of 
T regulatory cells, increased antibody response to pathogens) which point to chronically 
hyperactive innate and adaptive mechanisms39. 
 
3c.  The genetic basis of GTS (suggested 1000 words, is 1000 words, 32 additional refs) 
Peristera Paschou & Jeremiah Scharf  
 
Thoughts for Peristera & Jeremiah 
- Some type of “display item” (box, figure, table) might be useful  
- Note that the author guidelines ask that we “annotate 2–3 references from each main 
section describing why these papers are of particular importance”.  In this section 
you would only need to do 1 (30 to 50 word is ideal but 70 words maximum). 
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- Some minor comments in text to review 
 
Multiple twin and family studies have repeatedly demonstrated that GTS is one of the 
most heritable non-Mendelian neuropsychiatric disorders, with a recent population-based 
heritability estimate (h2) of 0.77 (95% CI, 0.70-0.85) and a 15-fold increased risk of 
GTS/Chronic Tic disorder to full siblings compared to that of the general population49-51.  
Despite this high heritability and nearly three decades of research on many large, 
multigenerational GTS families, no definitive GTS gene of major effect has been 
identified52,53. Instead, GTS appears to be highly polygenic, with a large proportion of disease 
heritability attributable to common risk variants distributed widely across the genome54.  
Inter-individual variation in polygenic burden, combined with rare, inherited or de novo 
mutations in a subset of patients, as well as environmental (i.e., non-genetic) factors may 
account for the substantial heterogeneity of the phenotype and its complex aetiology.  This 
genetic architecture parallels that of other developmental neuropsychiatric disorders such as 
schizophrenia and ADHD55,56.  While no individual genes have yet met statistical criteria as 
definitive GTS risk factors, several have been implicated and may provide intriguing clues to 
the neurobiology of the disorder. 
 
SLITRK1  
The implication of a member of the SLIT and TRK family of proteins (SLITRK1) in 
GTS aetiology has spurred intense debate.  Studying a patient with GTS with a de novo 
chromosome 13 inversion, Abelson and colleagues mapped one of the breakpoints 
approximately 350 kb from SLITRK1 and subsequently identified two rare, functional 
SLITRK1 mutations in three additional people with GTS: a single truncating, frameshift 
mutation (varCDfs) and two independent occurrences of a missense variant (var321) in the 3’ 
untranslated region (3’ UTR) that was demonstrated in vitro to alter a binding site for 
microRNA hsa-miR-189 and to impair neurite outgrowth57.  Subsequent sequencing and 
association studies have produced mixed results58-61 supporting the notion that, if SLITRK1 is 
involved in GTS aetiology, it may, however, only account for a small fraction of cases. 
 
HDC 
The recent discovery of a deleterious L-histidine decarboxylase (HDC) gene mutation in 
a GTS family with an affected father and eight affected children has raised the intriguing 
hypothesis of the involvement of neuronal histaminergic pathways in GTS 
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pathophysiology33.  HDC is the rate limiting enzyme in histamine biosynthesis and catalyses 
the oxidative decarboxylation of histidine to histamine.  Following up on a linkage signal on 
chromosome 15, Ercan-Sencicek and colleagues sequenced all genes within the linked 
interval and identified a single coding mutation, a premature termination codon (p. W317*, 
c.951G>A) that was not found in 1,500 European ancestry controls.  Subsequently, a 
genome-wide analysis of de novo GTS copy number variants (CNV) found enrichment in 
histaminergic pathway genes62, and a targeted study of 520 GTS nuclear families found a 
significant association to HDC tagging variants63, though the largest GTS genome-wide 
association study to date did not confirm this association64. 
 
Genome-wide association and copy number variant studies for GTS 
One GTS genome-wide association study (GWAS) has been published including 1285 
cases and 4964 ancestry-matched controls. No marker achieved genome-wide significance, 
though the strongest signal (p=1.85x10-6) was located within an intron of COL27A1, the type 
XXVII collagen alpha chain gene64.  A subsequent study of 42 of the top GWAS loci in 609 
independent cases and 610 ancestry-matched controls revealed the most significant GTS 
association to date with a SNP lying closest to NTN4, an axon guidance molecule expressed 
in the developing striatum65. 
  
Genome-wide investigations of copy number variation (CNV) in relation to GTS 
aetiopathogenesis have revealed multiple de novo or recurrent rare exon-affecting CNVs in 
various genes. The largest reported GTS CNV study to date (2,285 GTS cases and 3,791 
controls) identified two genome-wide significant loci (NRXN1, OR=20.2, p=7.6x10-5 and 
CNTN6, OR=6.0, p=1.7x10-4)66.  Rare NRXN1 deletions were also implicated in GTS 
pathogenesis in two previous studies of 111 and 210 GTS cases each67,68. In addition, 
recurrent exon-affecting microdeletions of the arylacetamide deacetylase (AADAC) were 
also observed in one of these early studies67 and recently identified in a larger meta-analysis, 
including a total of 1181 patients with GTS and 118,730 controls from six European 
countries (p=4.4×10-4)69.  
 
Shared genetic basis with other neuropsychiatric and neurological disorders 
The high rates of co-occurring psychiatric disorders in patients with GTS patients lend 
support to the hypothesis of shared/overlapping neural circuitry and genetic susceptibility70-
72.  Two studies analysed genome-wide genotyping data to examine the unique and shared 
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components of GTS and OCD heritability attributable to common (polygenic) variation54,73. 
Davis and colleagues demonstrated a significant proportion of shared heritability between the 
two disorders (r=0.41, se=0.15)54, though the majority of genome-wide OCD and GTS 
heritability was distributed differently across chromosomes and allele frequencies.  Yu and 
colleagues used polygenic risk scores to identify distinct differences between polygenic risk 
burden of OCD with and without co-occurring GTS/Chronic Tic Disorder73.  Also 
noteworthy is the significant overlap of rare GTS CNVs in loci previously shown to harbour 
recurrent deletions/duplications in other developmental neuropsychiatric disorders, including 
autism, ASD, schizophrenia, and epilepsy including 1q21, NRXN1, and 16p13.11 deletions, 
as well as 22q11 duplications67,74.  The first reported epigenome-wide association study for 
GTS, although limited in size, also found significant enrichment among the top hits in genes 
related to neuropsychiatric and neurological disorders75.  Another study independently 
identified an overall enrichment of CNVs spanning ASD genes62.  Lastly, singleton CNVs 
and chromosomal rearrangements have implicated cell adhesion molecules, such as neurexins 
and neuroligins, in GTS and other neurodevelopmental phenotypes.  
  
A recent large-scale cross-disorder study using GWAS summary statistics from 23 
different neurologic and psychiatric disorders demonstrated that a significant proportion of 
GTS polygenic heritability is shared with OCD, ADHD and migraine76.  While OCD and 
ADHD have long been known to share heritability with GTS70, the shared genetic 
relationship between migraine and GTS is novel.  GTS and migraine have been observed to 
co-occur more frequently than control rates77, and abnormal serotonin levels have been 
proposed in both disorders78. Interestingly, a cross-disorder meta-analysis of top loci from 
published GTS and ADHD GWAS studies79 reported the top signal (rs1866863, p=3.2x10-7) 
at TBC1D7 (the third subunit of the GTSC1/2 complex), which has been previously also 
implicated by GWAS in the aetiology of migraine.80  
 
4. Diagnosis, screening and prevention  
4a.  Symptoms and clinical course (suggested 1000 words, is 1127 words (excluding 
figure and caption), 16 additional refs) James Leckman  
 
Thoughts for Jim   
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Symptoms 
Tics are sudden, repetitive movements, gestures, or utterances that often mimic some 
aspect of normal behaviour3,81.  Usually of brief duration, individual tics rarely last more than 
a second.  Many tics tend to occur in bouts with brief inter-tic intervals of less than one 
second.  Individual tics can occur singly or together in orchestrated sequence.  They vary in 
their intensity and forcefulness.  Motor tics, which can be viewed as disinhibited fragments of 
normal movement, vary from simple, abrupt movements such as eye blinking, nose twitching, 
head or arm jerks, or shoulder shrugs to more complex movements that appear to have a 
purpose, such as facial or hand gestures or sustained looks.  These two phenotypic extremes 
of motor tics are classified as simple and complex motor tics, respectively.  One form of 
complex motor tics are referred to as dystonic tics: These tics involve the need to the 
individual to maintain a specific abnormal distorted posture for a period of time82.  Another is 
echopraxia, which entail the need to mimic a movement made by someone else in the 
immediate environment3,81,83. Similarly, phonic tics can be classified into simple and complex 
categories.  Simple vocal tics are sudden, meaningless sounds such as throat clearing, 
coughing, sniffing, spitting, or grunting.  Complex phonic tics are more protracted, 
meaningful utterances, which vary from prolonged throat clearing to syllables, words or 
phrases and to even more complex behaviours such as repeating one’s own words (palalalia) 
or those of others (echolalia) and, in rare cases, the utterance of obscenities (coprolalia)3,81,83.  
The severity of tics in GTS waxes and wanes throughout the course of the disorder. The 
tics of GTS and other tic disorders are highly variable from minute-to-minute, hour-to-hour, 
day-to-day, week-to-week, month-to-month and even year-to-year84.  Tic episodes occur in 
bouts, which in turn also tend to cluster85. Tic symptoms, however, can be exacerbated by 
stress, fatigue, extremes of temperature and external stimuli (i.e., in sensory and  in echolalic 
tics)81.  When individuals engage in behaviours that require focused attention and motor 
control, like playing the piano, reciting a poem, or participating in sport, their tics often 
completely disappear. 
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By late childhood a majority of individuals with tics are acutely aware of premonitory 
urges, i.e., feelings of tightness, tension or itching that are accompanied by a mounting sense 
of discomfort or distress that can be relieved only by the performance of a specific tic86,87.  
These premonitory urges are usually only experienced by young people older than ten years 
and indeed the widely used PUTS (Premonitory Urge for Tics Scale87) score increases after 
the age of ten years88.  These premonitory urges are similar to the sensation preceding an itch 
or a sneeze.  The majority of patients also report a momentary and fleeting sense of relief 
after a tic or bout of tics has occurred. Of note, most individuals are able to suppress their 
tics, but only for a limited period of time, and only with mounting discomfort. Of note, 
enhancing an individual’s awareness of their premonitory urges followed by a competing 
response is at the core of behavioural treatments that have proven to be the most effective89. 
Direct observational methods are the most objective measure of tic severity.  However, 
the frequency of tics varies dramatically according to setting and activity.  In addition, many 
individuals with GTS can suppress their symptoms for brief periods of time, thus clinical 
rating scales are the preferred method used by most clinicians experienced in evaluating tic 
disorders for assessing initial tic severity and for measuring change in tic severity. The Yale 
Global Tic Severity Scale (YGTSS) is the most widely used assessment tool that records an 
individual’s current repertoire of tics and estimates their severity based on the number, 
frequency, intensity, complexity, and interference associated with their motor and vocal tics 
viewed in separate aggregates90,91.  Among the currently available screening instruments, the 
Motor tic, Obsessions and compulsions, Vocal tic Evaluation Survey (MOVES) has been 
recommended as the most promising instrument for future epidemiological studies91,92. 
 
Clinical Course 
Tics usually have their onset in the first decade of life.  Boys are at increased risk to 
develop tics with a male-to-female ratio of 3 or 4 to 13,13.  Most investigators report a median 
onset of simple motor tics between five and seven years of age3,81.  The first symptoms 
usually occur in the head and neck area and may progress to include muscles of the trunk and 
extremities.  Motor tics generally precede the development of vocal tics and simple tics often 
precede complex tics.  Once present, individual tics can remain part of an individual’s tic 
repertoire for weeks to months, if not longer. That said, an individual’s tic repertoire typically 
evolves over time with new tics emerging. Most patients experience peak tic severity from 9 
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to 12 years of age following which there is a gradual decline in tic severity93,94 (See Figure 
XXXXX).  A complete remission of both motor and phonic symptoms can occur, but 
estimates vary considerably13,81,93 with some studies reporting rates of remission as high as 30 
to 50%93,94.  In such cases, the legacy of GTS in adult life is most closely associated with 
what it “meant” to have severe tics as a child.  For example, the individual who was 
misunderstood and punished at home and at school for their tics or who was teased 
mercilessly by peers and stigmatised by their communities will fare worse than a child whose 
immediate interpersonal environment was more understanding and supportive95.  
Intriguingly, in a study in which  patients were videoed when they were young and then at 
over twenty years of age at follow-up96, adult patients said they were "tics free", but on video 
it was demonstrated that 90% of the adults still had tics: However the tics no longer caused 
distress and the need for medication was much less96. 
Figure XXXXX: Course of Tic Severity in GTS 
 
 
 
 
 
 
 
 
Figure caption 
Plot of average tic severity in a cohort of 36 children aged 1 to 18 years94. Adapted with 
permission.  ARRTS (Annual Rating of Relative Tic Severity) is a parent-rating on a six-
point ordinal scale (Absent [0], least severe, mild, moderate, severe and most severe [6]). 
Similar data are also available from an independent cohort93. 
Tics typically have their onset between ages 4 to 6 years, reach their worst ever between 10 
and 12 years, and then decline in severity throughout adolescence. Tics can persist into 
adulthood and the most severe and debilitating cases occur in adulthood.  
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In contrast, adulthood is also the period when the most severe and debilitating forms of tic 
disorder are encountered.  In this small minority of adult patients, severe tics can persist or re-
emerge with frightening intensity.  At their worst, tics can be self-injurious and disabling, 
placing in serious jeopardy an individual's health and well-being. Indeed, treatment 
refractory, severe tics can lead to permanent disability and injury (e.g., severe head snapping 
tics leading to permanent injury to the cervical spinal cord or persistent eye-poking tics 
leading to blindness).  Adults with persistent severe tics often feel socially excluded and have 
resultant symptoms of a post-traumatic stress disorder.  These patients have also been the 
focus of experimental neuromodulatory interventions, including deep brain stimulation97,98. 
 
4b.  Comorbidity and co-existent psychopathology (suggested 1000 words, is 1253 words, 37 
additional refs) Mary Robertson  
Thoughts for Mary 
- May need to be shortened.  Reducing QoL section would save space and doesn’t 
detract from “core business” of comorbidity and co-existent psychopathology in this 
section. Please check refs are as intended 
- Note that the author guidelines ask that we “annotate 2–3 references from each main 
section describing why these papers are of particular importance”.  This means 1 or 
perhaps 2 from this section (30 to 50 words is ideal and 70 words maximum). 
- Some minor comments in text 
- Would your assessment measures Table fit here perhaps? 
 
 
 
In medicine and psychiatry, it is the ideal to give a patient only one diagnosis99. However, 
in many instances an individual patient has more than one diagnosable disorder. This is 
particularly true in individuals with GTS (), where only around 10% have "pure GTS" (i.e., 
tics only) whilst the remaining approximately 90% also have other  disorders, with this 
pattern arising both in community and clinical settings3. How should the relationship between 
these other disorders and GTS be described?  
 
NRDP – Gilles de la Tourette Syndrome    19 
 
 
The term comorbidity, first used by Feinstein100 regarding patients with rheumatic fever, 
defined as a " proven pathogenic mechanism" 101,102 and exemplified in the description of 
psoriasis and inflammatory bowel disease103, is now widely used in psychiatry104.  There are, 
however, varying definitions in use105,106, including within the GTS literature.  Although we 
have used comorbid and co-existent separately for some time5,107, the latter has otherwise 
rarely been used in the GTS literature, except when the tics are clearly secondary to insults 
such as head trauma, encephalitis, toxins, or have arisen post infection108. 
  
In GTS the best documented and  most common psychopathologies include ADHD (in 
around 60% of GTS clinic patients), then OCD [(40-60% of patients); ego-dystonic, 
symptoms for more than an hour a day] and Obsessive Compulsive Behaviours (OCB)  [(60-
90% of patients]; ego-syntonic, symptoms for less than an hour a day], and ASD (6-11%)3.  
A variety of other co-existent psychopathologies occur in GTS, including depression (13-
76%), non-OCD anxiety, separation anxiety, substance abuse and personality disorders.  
Other behavioural or emotional problems such as aggression, difficulties with anger control, 
sleep disturbances, self-injurious behaviours (SIB), and non-obscene socially inappropriate 
behaviours occur at higher rates than expected in people with tic disorders, usually when 
ADHD or OCD are already present.  In addition, learning problems (in about 30-40%) may 
co-exist in GTS3,109.  
 
We have chosen to use the term "comorbid" in GTS where the disorder in question is not 
only more common in GTS than in the general population, but there are also clinical 
similarities (although also differences)110 and a definite or purported genetic link exists 
between GTS and the disorder. We suggest the comorbid disorders meeting these criteria are 
include: i) OCD/OCB49, 54, 73, 110; ii) ASD111,  and CNVs62; and iii) ADHD111 See the section 
above on Shared genetic basis with other neuropsychiatric and neurological disorders for 
additional information..  
 
An exciting study showed that the lifetime prevalence of any psychiatric disorder being 
associated with GTS was 85.7%, and 57.8% of individuals withGTS had two or more 
additional psychiatric disorders70. Moreover, the mean (SD) number of associated disorders 
was 2.1 (1.6), but when OCD and ADHD were excluded, this reduced to 0.9 (1.3), given 
72.1% of the GTS group also met criteria for ADHD or OCD.   Other disorders including 
mood, anxiety and disruptive behavioural disorders, were each thought to occur in about 30% 
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of individuals. The authors therefore suggested that genetic correlations between GTS and 
mood, anxiety and disruptive behavioural disorders may be accounted for by ADHD; whilst 
mood disorders may be accounted for by a genetic relationship with both ADHD and OCD.  
They also showed that GTS and substance abuse were not genetically related.  These results 
are in keeping with others who have shown no genetic relationships between GTS and 
depressive and anxiety disorders113, and conduct disorders114. Eapen & Robertson5 reported  
in a sample of 222 patients, that those with “pure GTS” (13.5%) had no coprolalia and 
intriguingly, that pure GTS was associated with no family history of OCD suggesting that 
additional genes or environmental factors may be at play when GTS  is associated with 
comorbidities.  
Both OCB/OCD115 and ADHD116 have been widely studied and documented in individuals 
with GTS.  It has also been suggested in at least one study that OCB was associated with the 
presence of ADHD and also with SIB117-119. 
  
We would therefore argue that, at present, GTS is understood to be genetically related 
in some GTS patients to OCD/OCB, ADHD and ASD, but not to depression, anxiety, 
disruptive behaviours, conduct disorder and substance abuse, We further suggest that OCD/B, 
ADHD and ASD are therefore comorbid, whilst the latter disorders are co-existent with GTS. 
However, it must be remembered that recent studies have demonstrated that the genetics of 
GTS and associated disorders are far from simple54,73. 
 
When discussing phenotype, we first acknowledge that there are many "tic 
phenotypes"(eg dystonic tics) and  associated neurological conditions, especially migraine3. 
Further, with respect to phenotyping studies, of importance is that in all eight investigations 
to date – despite using differing methods including using cluster analysis, latent class 
analysis, hierarchical cluster analysis and principal component factor analysis - have reported 
several classes (phenotypes), based on tics (7/8), behaviours and comorbidities as per based 
on tics.  The resulting phenotypes have included variously OCD/B, ADHD, depression, 
phobias and panic attacks120. The only one phenotype that has been replicated however is 
“Pure GTS”. Interestingly, coprolalia does not seem to be class specific, other than not 
arising in Pure GTS5. Clearly, with regard to psychopathology, more research is required.   
 
While we will discuss Quality of Life (QoL) later in detail, note that several recent 
studies have demonstrated that the comorbidities and psychopathologies encountered with 
NRDP – Gilles de la Tourette Syndrome    21 
 
 
GTS have a disproportionate negative impact on QoL (121, 122) with GTS having poorer 
QoL than healthy controls and people with epilepsy: in addition ADHD and OCD/B had 
widespread, if differential, effects on QoL scores, and were in combination the best predictors 
of QoL.  In another controlled study, individuals with GTS  had poorer psychosocial 
outcomes than healthy controls and this was associated not only with tic severity but also 
specifically ADHD and OCD127. Other factors encountered in patients with GTS but for 
which the ADHD is largely responsible, include maladaptive behaviours and decreased 
cognitive functioning in young people124, greater substance abuse, more aggression and more 
encounters with the justice system128. In summary, there is a consensus that comorbidities in 
general have a profound negative effect on the QoL, social functioning and peer relationships 
of patients with GTS while people with GTS and ADHD have significantly more maladaptive 
behaviours across the lifespan.  
  
One of the major co-existent psychopathologies that occurs in GTS is depression with 
13-76% of all patients with GTS affected129, and in controlled studies involving over 700  
patients with GTS, those with GTS are more depressed than controls129. Clinical correlates of 
depression include echo- and coprophenomena, premonitory sensations; sleep disturbances, 
self-injurious behaviours; childhood Conduct Disorder; OCD/B and ADHD. Depression also 
leads to lower QoL, and potentially to hospitalisation and suicide. It was suggested that the 
aetiology of the depression in the context of GTS was multifactorial129 but not genetic113 and 
may be related to the OCD70. 
  
Caregiver burden, rarely studied, was shown to be significantly higher in parents of 
young people with GTS when compared to parents of matched young people with asthma. 
The two groups were significantly different with parents of young individuals with GTS 
being the most disadvantaged. The correlates of increased caregiver burden and greater 
parental psychopathology included a GTS diagnosis and behavioural difficulties130. 
 
Finally, suicidality (thoughts/ideation or behaviours including deliberate self-harm), is 
an important but relatively neglected aspect of GTS research with studies showing a higher 
prevalence in GTS (9.7%)  when compared to healthy controls (3%) 131. Since the first 
documentation of completed suicide in GTS by Robertson and colleagues132, few studies 
have examined this in detail with findings suggesting that factors associated with suicidality 
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include tic-related factors such as severity, coprolalia, SIB etc. and the presence of co-
morbidities and co-existent psychopathologies.     
 
5. Management 
5a.  Psychopharmacologic treatments (suggested 800 words, is 895 words, 14 additional 
refs) Veit Roessner  
 
Thoughts for Veit 
- Need to cut some words 
- Some minor comments in text, including question about references to include for main 
points and about potentially including some type of display item (figure, table, 
flowchart etc.).  
- Note that the author guidelines ask that we “annotate 2–3 references from each main 
section describing why these papers are of particular importance”.  In this section, 
you would need to do 1 only (30 to50 words is ideal and 70 maximum). 
 
As a consequence of the high individual variability, idiosyncratic response to 
medications and complexities in symptom presentation and resulting impairment, decisions 
when and how to treat tics differ significantly across patients with GTS, particularly in 
children and adolescents. There are no psychopharmacologic or other "cures" in GTS, nor 
clear evidence that not starting treatment has a negative impact on the prognosis of the core 
tic symptoms. 
 
For most individuals with GTS whose tics are mild-to-moderate and do not impair social 
functioning, the provision of psychoeducation and exploration of associated coping strategies 
is typically sufficient. If additional treatment is indicated, this should be based on the most 
prominent and disabling symptoms, which often are not tics (see the European Society for the 
Study of Tourette syndrome (ESSTS) guidelines for a GTS management decision-tree136).  In 
addition to tic severity, the ESSTS guidelines suggest tic-specific psychopharmacotherapy 
should be considered where tics are causing i) pain or injury; ii) social and emotional 
problems (e.g., reactive depressive symptoms); and/or iii) functional interference (e.g., 
impairing  academic achievement)136, in the context where behavioural therapies are either 
not available or not the patient’s preference. 
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With respect to managing the key comorbidities, prescribing practices used when GTS is 
not present generally apply.  It is now widely held that stimulants can be used to manage 
comorbid ADHD without much deleterious impact on tic severity in the majority of 
patients137.  Non-stimulant ADHD treatment options such as atomoxetine, guanfacine and 
clonidine are also available8.  Comorbid OCD can be managed with cognitive behavioural 
therapy and/or medication such as SSRIs or clomipramine, as per published guidelines138, 
similarly for depression where lower SSRI doses are typically required139. 
 
The choice of psychopharmacologic treatment of tics is still often based on personal 
experience and there are widespread methodological limitations in the extant evidence base.  
An additional impediment to the development of a consensus psychopharmacological 
treatment algorithm for tics is the waxing and waning course of GTS.  Moreover, tic severity 
can be influenced by comorbid disorders, which, apart from some exceptions, are not targeted 
by anti-tic medications. 
 
The aim of psychopharmacologic treatment of GTS is to ameliorate tics and to improve 
psychosocial functioning as soon as possible with as few adverse effects as possible. On 
average, medication can reduce tics dose-dependently by 25-70% and normally within two-
to-four weeks.   “Over-medication”, driven by the belief that higher dosages will necessarily 
be more effective, can cause significant adverse reactions (see α-2-agonists below), 
particularly sedation, apathy and extrapyramidal effects, in addition to weight gain and 
metabolic abnormalities. 
 
Since the first case reports of haloperidol use in GTS in 19616,7 and subsequent open-
label studies in the 1970s and 1980s, mainly using haloperidol and pimozide, there is both 
increasing evidence from clinical trials and broad clinical consensus that dopamine receptor 
blockers lead to a good response for motor and behavioural symptoms in the majority of 
patients. For those who do not respond to a particular agent, a switch to another dopamine 
receptor blocker or group of agents as well as combining two agents will generally lead to the 
desired benefits.  There is only a minority of patients who evidence refractoriness to 
psychopharmacological treatment for tics, however the exact percentage is difficult to 
quantify, partly because the first definition has only recently been published140. 
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In general, there is no difference in efficacy among the different dopamine receptor 
blockers (haloperidol, pimozide, sulpiride, tirapride, risperidone, ziprasidone), however the 
adverse effect profile is very different with respect to weight, prolactin and other factors141, 
and the tolerability profile and the treatment requirements of the comorbid conditions have to 
be considered142,143. In this context, it is not surprising that the substituted benzamides, 
particularly sulpiride and tiapride, have been recommended as first line treatment of GTS 
mainly in Europe because of their favourable benefit to risk ratio141,144 but unfortunately, both 
have too little evidence from randomised control trials, potentially because of low interest 
from an economic perspective, despite there being excellent efficacy in routine clinical care.  
With respect to differences in prescribing patterns internationally, in the United States and 
Canada, α-2-agonists (clonidine and guanfacine) are considered first-line therapy, primarily 
because of their preferable side-effect profile compared with typical antipsychotics.  In a 
recent meta-analysis, superiority to placebo for both α-2-agonists was confirmed, however, 
this benefit was significant only for children/adolescents with GTS and comorbid ADHD, 
and minimal in patients with GTS without ADHD145. Thus, while dopamine blocking agents 
such as haloperidol is still the mainstay of tic-treatment internationally based on availability, 
due to the numerous adverse reactions of typical antipsychotics, second generation 
antipsychotics such as Risperidone is being used widely where available and more recently 
the better tolerated agents such as aripiprazole are being favoured, where cost and availability 
permits, as they appear to have the best benefit to risk ratio141. 
 
Finally, it is noteworthy that interest remains in alternative agents, particularly in cases 
refractory to classical agents146. These patients often suffer from more severe and very 
complex symptomatology.  There is some promising evidence regarding cannabinoids147.  In 
addition, numerous other agents have been tried for the treatment of tics (e.g., tetrabenazine, 
baclofen, pramipexol, ecopipam, topiramate, naloxone, naltrexone, calcium channel blockers, 
flutamide, lecithin, metoclopramide, ondansetron, physostigmine, propranolol) with varying 
benefits and a number of new agents are currently either in development or in clinical trial 
phase148.  Complementary and alternative medicine approaches such as Ω-3 fatty acids and 
Chinese Traditional Medicine (Ningdong granule) have recently attracted growing interest149.  
 
5b.  Behavioural treatments (suggested 600 words, is 524 words, 13 additional refs) 
Doug Woods  
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Thoughts for Doug 
- MMR wrote – Doug, I feel a table/figure would be nice - we could get copyright from 
JAMA or JAMA Psychiatry - given that we have time - a new table from you showing 
effect sizes for CBIT/HRT would also be good - the only thing is that my sense is that 
readers for our NRDP paper - wish a good up to date state of the art summary - they 
are unlikely to read all GTS papers in detail - & may not know all tables etc.  As long 
as ours is informative & up to date maybe this is your call 
 
- Note that the author guidelines ask that we “annotate 2–3 references from each main 
section describing why these papers are of particular importance”.  In this section, 
you would need to do 1 only (30 to 50 words is ideal, 70 maximum). 
 
Behavioural treatments are based on the idea that tics are influenced by contextual 
forces.  By restructuring contextual factors and teaching patients tic-inhibition skills, 
symptoms can be effectively managed.  Habit reversal therapy (HRT)150 was the first 
behavioural treatment with a significant evidence base.  HRT involves three primary 
components; awareness training, competing response training, and social support.  In HRT, 
tics are treated one at a time; at a rate of one per week.  In awareness training, the patient 
learns to notice tics as they occur or when the premonitory urge to tic appears. In competing 
response training, the patient learns to do an action that prevents the target tic from occurring.  
The patient uses this “competing response” contingent on the urge to do the target tic or on 
the tic itself.  Competing responses are to be held for one minute or until the urge goes away; 
whichever is longer. With social support, an identified "support person" praises proper use of 
the competing response and prompts proper use when the patient forgets to do so. 
 
Building on traditional HRT procedures, treatment researchers have started to include 
function-based treatment elements.  In using function-based procedures, therapists assess 
contextual factors that reliably increase tics and reactions to tics that may inadvertently 
reinforce tics.  The clinician then suggests therapeutic strategies that may reduce tics, to the 
patient and/or his or her parents.  The strategies suggested are directly linked to the results of 
the assessment. 
 
In addition to HRT and function-based interventions, relaxation training, 
psychoeducation about GTS, and a reward procedure to enhance treatment compliance have 
been added to treatment.  Implemented in 8, structured 60-90 minute sessions over 10 weeks, 
this comprehensive behavioural intervention for tics (CBIT)151 was tested through two large 
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randomised controlled trials89,152.  Both studies compared CBIT to a psychoeducation and 
supportive therapy control condition.  Children with GTS who received CBIT showed 
significant improvements in tics and tic-related impairment at the end of acute-phase 
treatment relative to those receiving supportive therapy.  Furthermore, 6-month follow-up 
data of treatment responders showed that gains were maintained and associated with 
significant decreases in anxiety and disruptive behaviours relative to baseline89.  Wilhelm and 
colleagues studied adults with GTS and found that those receiving CBIT demonstrated 
significant reductions and tics and tic-related impairment at the end of acute-phase treatment 
relative to supportive therapy.  Gains were maintained for post-treatment responders at the 6-
month follow-up152.  In both studies, adverse events were tracked, and none were associated 
with CBIT.  Based largely on these two large studies, CBIT has been recommended as a first-
line treatment for those with GTS in multiple practice guidelines153-155. 
 
Researchers have attempted to effectively disseminate CBIT. CBIT delivered via 
teleconferencing devices have been shown to be as effective as face-to-face delivery156, and 
CBIT has also been shown to be effectively delivered via Skype157, and in abbreviated format 
as delivered by nurse practitioners158. 
 
The mechanisms by which CBIT is effective are unclear, but suggested processes include 
improved motoric inhibition and habituation to the aversive premonitory urge.  Nevertheless, 
few studies exist that have adequately tested these hypotheses159,160. 
 
CBIT is the most  well-studied behavioural treatment, but  exposure and response 
prevention161 and cognitive physiological therapy162 appear promising in pilot tests. 
 
5c.  Surgery (Deep Brain Stimulation) (suggested 350 words, is 403 words, 6 additional 
refs) Marwan Hariz 
 
Thoughts for Marwan 
- Note that the author guidelines ask that we “annotate 2–3 references from each main 
section describing why these papers are of particular importance”.  In this section, 
you would need to do 1 only (30 to 50 words is ideal and 70 words maximum). 
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A survey of PubMed (June 18, 2016) on Deep Brain Stimulation (DBS) and GTS yielded 
232 publications, far more than the number of published patients who have undergone DBS. 
Vandewalle, who pioneered DBS for GTS in 1999, recently noted that “DBS has emerged as 
an established effective and safe treatment option for a small subset of patients with severe 
GTS...”163.  She also highlighted, however, the paucity of evidence-based publications (5 
reports on a total of 32 patients worldwide), the heterogeneity of results, and the lack of 
consensus on “best” brain target, all of which point to the fact that DBS for GTS remains 
anything but “established”.  Deeb and colleagues documented recently the International GTS 
DBS registry, totalling 157 patients to date: of these 58.5% had DBS in the thalamus and 
39% in the GPi164. 
 
Some of the issues surrounding DBS in GTS are related to the small number of patients 
who would actually “require” surgery (as reflected in the great difficulty to recruit “suitable” 
patients for DBS trials) and to the syndrome itself, such as the young age of most patients, the 
waxing and waning course, the variability in GTS phenotypes and comorbidities. 
 
Numerous issues contribute to the difficulty in deciding which of the hitherto nine 
trialled brain targets165,166 within the basal ganglia thalamo-cortical circuitries of GTS 
disorders (which involve motor networks for tics and limbic-associative ones for 
comorbidities), is the “best” target for DBS, and little is known concerning the predictive 
selection criteria for efficacy of DBS for both tics and/or psychiatric comorbidities and co-
existent behaviours and psychopathologies. Additionally, it is documented that the rate of 
infection of DBS hardware seems increased in patients with GTS patients167,168. Whether this 
is due to tic-related behaviours and comorbidity (e.g., picking at wound), or distinct 
immunological profiles remains unclear168. 
 
The recent initiative of the Tourette Association of America to launch an international 
GTS DBS registry and database to share data, uncover best practices, improve outcomes, and 
to provide information to regulatory agencies, is a step in the right direction164.  Despite 17 
years of surgery for GTS, there is still no consensus about the best brain target for DBS, and 
this procedure remains investigational, and is still far from “established”, although it may be 
legitimate to offer DBS to patients where other options have been exhausted, especially in 
patients in whom the severity of refractory motor tics threatens their life or risks inducing 
irreversible neurological deficit167. 
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6. Quality of Life [suggested 500 words, is 499 words – 17 additional refs] Valsamma 
Eapen and Rudi Črnčec  
Thoughts for Valsa and Rudi 
- Note that the author guidelines ask that we “annotate 2–3 references from each main 
section describing why these papers are of particular importance” (70 words would be a 
long annotation). 
- Need to reconcile this with any comments on QoL MMR makes in 4b.  Comorbidity and 
co-existent psychopathology: MMR I have reduced mine - BUT more to go - but yours 
has increased to 586 as I moved some of my QoL text to your section 
 
Elstner and colleagues169 first observed in 2001 that patients with GTS had lower 
Quality of Life (QoL) than the general  population and patients with epilepsy.  Consistent 
with the idea that GTS is more than having motor and vocal tics, subsequent studies have 
highlighted the compounding effect of a number of factors in reducing QoL170.  In addition to 
tic severity and the presence of coprophenomena, these factors include associated clinical 
features such as self-injurious behaviours, non-obscene socially inappropriate behaviours, 
and social difficulties; co-morbidity with OCD/OCB and ADHD; and co-existing 
psychopathologies including depression, and drug and alcohol use.  As expected, it has 
recently been reported that patients with "Pure GTS" have higher QoL than GTS-Plus-Co-
morbidities groups123. 124   In multiple regression analysis, the number of comorbid/co-
existent diagnoses and the presence of coprophenomena emerged as significant predictors of 
poorer QoL123 Meta-analysis has suggested that factors affecting QoL may vary across the 
lifespan, with tic severity, ADHD, and OCD particularly associated with lower QoL in 
children, whereas in adults anxiety and depression become increasingly relevant170,171.  .   
Another study125 reporting on young individuals with GTS found self-reported strong 
associations between comorbidity and decreased global QoL, increased emotional 
symptomatology, impaired emotional and school functioning as well as impaired social 
functioning and peer relationships. The primary care-givers of the youth with GTS separately 
reported that the youngsters experienced lower QoL, increased emotional, behavioural and 
social difficulties, and elevated rates of insecure peer attachment relative to controls126.  
  Patients may develop coping strategies over time to manage difficulties that are 
prominent in childhood, which may also moderate with age, only to then be confronted with 
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new challenges into adulthood.  There are also likely to be reciprocal QoL effects upon 
parents and family members, although these are presently less well understood172. 
 
A number of quality of life domains are impacted, including psychological, obsessional, 
social, physical, school/work-based, and cognitive173.  As a consequence to these, 
psychological distress, frustration, and depression are commonly experienced by patients 
with GTS121,174, and there is mounting evidence that depression exerts a powerful negative 
effect upon QoL175,176.  Depressed mood and low QoL may be outcomes of the heavy 
psychosocial burden that can be experienced over time177.  OCD/OCB also contributes to this 
psychosocial burden, and there is evidence that obsessionality and perfectionism may make 
the process of adapting to a life with tics more difficult. Social skills difficulties and poor 
peer relationships are common in GTS178-181, as are the additional difficulties of dealing with 
stigma and bullying.  Severe tics can result in physical pain and injuries182 as well as in 
difficulties with activities of daily living, including exercise183.  School-based problems 
including academic problems, especially in the context of ADHD, have been noted in a 
number of studies - which underscore the importance of teacher knowledge, understanding 
and flexibility.  Reduced concentration and inability to complete important tasks encompass 
cognitive aspects of QoL.  Finally, while age-dependent improvement of comorbid ADHD 
seems likely to have a significant impact on cognitive functioning128, results from the 
Tourette Syndrome Impact Survey study highlighted a significant correlation between tic 
severity and cognitive domain scores182. 
 
Thus, there are multiple pathways to negative impacts on QoL in patients with GTS, with 
these often co-occurring in an additive manner (see Figure XXXXX).  As a subjective marker 
of well-being, QoL has emerged during the past 15 years as an important component in 
understanding the experience of patients with GTS, and as a key assessment and treatment 
target in its own right.  Several GTS-specific tools have been developed that will facilitate the 
incorporation of QoL into research studies and clinical practice184,185.   
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Figure XXXXX.  Stylised depiction of Quality of Life domains affected in GTS 
 
7. Outlook 
 
7a.  Genetics (suggested 500 words, is 502 words, 21 additional refs) Jeremiah  and 
Carol  
Thoughts for Jeremiah and Carol 
- Note that the author guidelines ask that we “annotate 2–3 references from each main 
section describing why these papers are of particular importance”.  In this section 
one or two would suffice (30 to 50 words is ideal, 70 words maximum). 
 
The field of GTS genetics is poised for an upsurge in discovery of definitive GTS 
susceptibility genes in the next five years.  The most recent GWAS, CNV and sequencing 
studies have each indicated the presence of a significant number of GTS genetic risk variants 
in aggregate, and current sample sizes are approaching those at which other polygenic 
disorders, such as schizophrenia and height, began to identify individual genes with 
certainty186,187.  Based on the trajectory of gene discovery in those disorders, there is strong 
evidence for the presence of a GWAS “inflection point”, corresponding to the sample size 
(~10,000 cases for schizophrenia) at which a study is adequately powered to identify any one 
of possibly hundreds of small-effect, polygenic risk variants186.  While GWAS below this 
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sample size have minimal power to identify definitive disease loci, once the "inflection point" 
is reached, new gene discovery takes on a linear relationship with sample size, resulting in 
~1-4 new genes for every 1000 additional cases.  Parallel accelerations in disease gene 
discovery for CNVs and de novo, gene-disrupting coding mutations also have been observed, 
suggesting that large-scale, rare variant discovery efforts will be equally successful188,189.  As 
such, the success of GTS genetics will require continued expansion of international genetic 
collaborations and concerted efforts to identify innovative approaches to large-scale sample 
collection.  On the collaborative front, US and European GTS genetics consortia have already 
harmonised phenotypic assessments and established pre-publication data sharing and joint 
meta-analyses53,65.  For sample collection, multiple strategies are being pursued, including 
leveraging of data-rich electronic health records linked to biobanks190, identifying cases 
among population registry studies with available DNA191 and development of validated, 
internet-based assessments combined with local biospecimen collection to bring sample 
collection to subjects, rather than focusing on collections limited to academic medical centres 
with GTS specialty clinics192,193.  In fact, the NIMH Strategic Plan identified GTS as a 
priority disorder for expansion of DNA (Strategy 1.2, Priority A.4194).  
 
Once GTS susceptibility variants are identified, the often-discussed challenge of 
transitioning from genes to biology will benefit greatly from technologic advances in systems 
biology and international efforts to generate large-scale, publically available gene expression 
and epigenomic datasets from multiple mouse and human brain regions across different 
neurodevelopmental time points195-197.  These spatiotemporal maps of gene activity and gene 
regulation will be instrumental in pinpointing the specific brain region(s) and critical periods 
where susceptibility genes influence GTS pathophysiology at the molecular level198,199.  In 
parallel, collaborations in the field of neuro-imaging genetics (the largest example of which is 
the ENIGMA Consortium)  will facilitate integration of GTS genetics with systems 
neuroscience to uncover underlying GTS biology at the neural circuit level200,201. 
 
A third strategy already in progress is to leverage data from related neuropsychiatric 
disorders to identify gene variants in common across these disorders202,203.  The Psychiatric 
Genomics Consortium (PGC) has led the field in this work204,205 and both GTS and OCD 
consortia have joined the latest PGC cross-disorder analyses. Similarly, the emergence of 
robust, alternative symptom-based GTS phenotypes that cut across traditional diagnostic 
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boundaries may benefit GTS genetics, neuro-imaging and treatment studies by addressing 
phenotypic heterogeneity and comorbidity206. 
 
7b.  General (suggested 500 words, is 500 words, 3 additional refs) Valsamma Eapen  
Thoughts for Valsa 
- Note that the author guidelines ask that we “annotate 2–3 references from each main 
section describing why these papers are of particular importance”.  In this section 
one or two would suffice (70 words would be a long annotation). 
As described above, unprecedented opportunities currently exist in unravelling the 
etiopathogenesis of GTS through concerted international efforts but at this point we have 
limited understanding of the pathophysiology with unresolved questions on what 
constitute GTS phenotypes, and the modulators of phenotypic variability. While genetic 
factors further modified by gender and a number of non-genetic factors, or ‘second hits' 
(e.g. prematurity, perinatal trauma/injury/hypoxia, oxidative stress, 
infections/inflammations/autoimmunity, neural and psychosocial stressors) have all been 
implicated in the pathogenesis36-38, these are not unique to GTS and are shared by a 
number of neurodevelopmental disorders (NDs). In this regard, a common association 
exists between GTS and other NDs including autism through neurodevelopmental genes 
such as the neurexin superfamily genes (e.g. neurexins and neuroligins) and the neurexin 
trans-synaptic connexus (NTSC) which regulates behaviour control207. Consequently 
dysregulation of the relevant genes can render varying pathogenic consequences for brain, 
mind, and behavior208 resulting in a wide range of phenotypic presentations characteristic 
of GTS, Autism, ADHD, OCD etc. Cross disorder analysis examining genetic 
determinants to endophenotypic (e.g. neuroimaging) and clinical phenotypic 
characteristics in these NDs is expected to ultimately clarify the overlaps and delineations 
in the pathogenesis.     
Although the precise pathophysiological basis of GTS remains unresolved, there is 
converging evidence to suggest involvement of the CSTC circuitry that mediates the 
integration of movement, sensation, emotion and attention, and the dopamine system that 
regulates the motor circuitry16.  While the dopamine model has gained much attention 
through clinical treatment studies, recent research including preclinical studies and post-
mortem findings have highlighted the role of careful calibration of the excitatory–
inhibitory balance through glutamate and GABA in conjunction with other 
neurotransmitter systems as described earlier. Further, animal studies could assist in 
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informing the impact of specific genetic and epigenetic influences on molecular pathways 
and cellular development/circuitry formation along with opportunities for new treatment 
development. Thus a deeper understanding of the neurochemical systems in GTS will 
ultimately translate to empirically supported pharmacological interventions (a number of 
such agents are currently under trial)148 while neurophysiological studies will unravel the 
mechanism of action in brain stimulation techniques such as transcranial magnetic 
stimulation (rTMS) 209 and  transcranial Direct Current Stimulation (tDCS) (Clinical 
Trial: ACTRN12615000592549).  
Animal models of tic generation and the impact of modulating factors such as stress 
and infections  will help elucidate the complex interplay between genetic, environmental 
(e.g. pre- and peri-natal) and neuroimmunological risk factors, which affect the phenotype 
and outcome. Further, gene-by-environment and epigenetic studies will provide valuable 
clues to the GTS pathophysiology.   
From a clinical and epidemiological perspective, it is important to reconcile the wide 
variations in prevalence rates ranging from 0.25% - 5.7%3 consequent to the varying 
methodology, changing diagnostic criteria over the years and the use of different 
assessment schedules in different studies which has made both comparison and pooling of 
data difficult. Future research using uniform methodology to inform longitudinal course 
and predictors of long term outcome, including focus on individual variability in tic 
symptoms are important considerations along with risk and resilience factors for 
successful long-term outcomes.   
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